Home > Haematology > CAPTIVATE: Ibrutinib plus venetoclax show stunning efficacy in CLL

CAPTIVATE: Ibrutinib plus venetoclax show stunning efficacy in CLL

Expert
Prof.  Paolo Ghia, Università Vita-Salute San Raffaele, Italy

Notice: Undefined index: new_doi_fields in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 138

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 138

Notice: Undefined index: new_doi_fields in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 174

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 174

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 175
Conference
ASH 2021
Trial
Phase 2, CAPTIVATE
The first-line, chemotherapy-free regimen of ibrutinib plus venetoclax showed ongoing efficacy after 2 years of follow-up in patients with chronic lymphocytic leukaemia (CLL). Patients with confirmed undetected Minimal Residual Disease (uMRD) did not display MRD relapses, death, or progressive disease during the follow-up phase of the international, multicentre, phase 2 CAPTIVATE (NCT02910583) trial. Follow-up results after 2 years of the CAPTIVATE trial were presented during the American Society of Hematology (ASH) annual meeting, held from 11-14 December, 2021. Medicom spoke with Prof.  Paolo Ghia (Università Vita-Salute San Raffaele, Italy) to discuss the results of the trial [1]. The CAPTIVA...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on